These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28063649)

  • 1. Biologic drugs as analgesics for the management of osteoarthritis.
    Dimitroulas T; Lambe T; Klocke R; Kitas GD; Duarte RV
    Semin Arthritis Rheum; 2017 Jun; 46(6):687-691. PubMed ID: 28063649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic Drugs as Analgesics for the Management of Low Back Pain and Sciatica.
    Dimitroulas T; Lambe T; Raphael JH; Kitas GD; Duarte RV
    Pain Med; 2019 Sep; 20(9):1678-1686. PubMed ID: 30576566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs.
    Cao Z; Zhou J; Long Z; Li Y; Sun J; Luo Y; Wang W
    Aging (Albany NY); 2020 Dec; 13(1):1051-1070. PubMed ID: 33293475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Treatment Options for Osteoarthritis.
    Hermann W; Lambova S; Muller-Ladner U
    Curr Rheumatol Rev; 2018; 14(2):108-116. PubMed ID: 28875826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials.
    Persson MSM; Sarmanova A; Doherty M; Zhang W
    Rheumatology (Oxford); 2018 Oct; 57(10):1830-1837. PubMed ID: 29917100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropathic pain in osteoarthritis: a review of pathophysiological mechanisms and implications for treatment.
    Dimitroulas T; Duarte RV; Behura A; Kitas GD; Raphael JH
    Semin Arthritis Rheum; 2014 Oct; 44(2):145-54. PubMed ID: 24928208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?
    Bannwarth B; Kostine M
    Drugs; 2017 Sep; 77(13):1377-1387. PubMed ID: 28660479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nerve growth factor: an update on the science and therapy.
    Seidel MF; Wise BL; Lane NE
    Osteoarthritis Cartilage; 2013 Sep; 21(9):1223-8. PubMed ID: 23973134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?
    Bannwarth B; Kostine M
    Drugs; 2014 Apr; 74(6):619-26. PubMed ID: 24691709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term analgesic effect of a single dose of anti-NGF antibody on pain during motion without notable suppression of joint edema and lesion in a rat model of osteoarthritis.
    Ishikawa G; Koya Y; Tanaka H; Nagakura Y
    Osteoarthritis Cartilage; 2015 Jun; 23(6):925-32. PubMed ID: 25677108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain.
    McNamee KE; Burleigh A; Gompels LL; Feldmann M; Allen SJ; Williams RO; Dawbarn D; Vincent TL; Inglis JJ
    Pain; 2010 May; 149(2):386-392. PubMed ID: 20350782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy for osteoarthritis-related pain: current and emerging therapies.
    Zhang M; Wang Z; Ding C
    Expert Opin Pharmacother; 2024 Jun; 25(9):1209-1227. PubMed ID: 38938057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain.
    Miller RE; Malfait AM; Block JA
    Clin Exp Rheumatol; 2017; 35 Suppl 107(5):85-87. PubMed ID: 28967370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complexities in the pharmacologic management of osteoarthritis pain.
    McCarberg B; Tenzer P
    Curr Med Res Opin; 2013 May; 29(5):539-48. PubMed ID: 23489409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of biologic agents for the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials.
    Meng F; Li H; Feng H; Long H; Yang Z; Li J; Wang Y; Xie D
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221080377. PubMed ID: 35282570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis.
    von Loga IS; El-Turabi A; Jostins L; Miotla-Zarebska J; Mackay-Alderson J; Zeltins A; Parisi I; Bachmann MF; Vincent TL
    Ann Rheum Dis; 2019 May; 78(5):672-675. PubMed ID: 30862648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models.
    Britti D; Crupi R; Impellizzeri D; Gugliandolo E; Fusco R; Schievano C; Morittu VM; Evangelista M; Di Paola R; Cuzzocrea S
    BMC Vet Res; 2017 Aug; 13(1):229. PubMed ID: 28768536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies for the treatment of osteoarthritis.
    Zheng S; Hunter DJ; Xu J; Ding C
    Expert Opin Biol Ther; 2016 Dec; 16(12):1529-1540. PubMed ID: 27562879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analyses of osteoarthritis oral therapies: a systematic review.
    Wielage RC; Myers JA; Klein RW; Happich M
    Appl Health Econ Health Policy; 2013 Dec; 11(6):593-618. PubMed ID: 24214160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging atlas for eligibility and on-study safety of potential hip adverse events in anti-NGF studies (Part 2).
    Roemer FW; Hayes CW; Miller CG; Hoover K; Guermazi A
    Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S43-58. PubMed ID: 25527219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.